Every figure cited here was generated by studies of the FDA-approved tirzepatide product.

Mechanism, in brief

Tirzepatide is a single molecule that activates two incretin receptors at once. The glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor are the two pathways the gut uses to signal the pancreas after a meal. Engaging both produces glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, and reduced food intake through hypothalamic appetite circuits.

The published signaling work suggests that tirzepatide engages GIP with affinity comparable to native GIP but binds GLP-1R roughly 18 to 20-fold weaker than native GLP-1, while biasing GLP-1R signaling toward cAMP over beta-arrestin recruitment^[6]. That signaling pattern, the imbalanced and biased fingerprint as the original authors named it, is the proposed molecular basis for the differentiated clinical effect observed in head-to-head trials^[3].

The pharmacokinetics support once-weekly subcutaneous dosing. The elimination half-life is approximately 116 to 120 hours — around five days — with steady-state reached after roughly four weeks; tmax falls between 24 and 72 hours after injection; plasma protein binding exceeds 99 percent via the C20 fatty diacid moiety^[8].

SURPASS — type 2 diabetes

The SURPASS Phase 3 program enrolled roughly 6,000 adults with type 2 diabetes across five global trials. Tirzepatide at 5, 10, and 15 mg subcutaneous once weekly produced HbA1c reductions of -1.9 to -2.6 percent and body-weight reductions of 6.6 to 13.9 percent across the program. At the highest dose, up to 97 percent of participants reached HbA1c below 7 percent — a control rate not previously documented at scale in a peptide therapeutic^[10].

SURPASS-2, the head-to-head trial against semaglutide 1 mg in 1,879 adults with type 2 diabetes inadequately controlled on metformin, produced a -2.30 percent HbA1c reduction in the 15 mg arm versus -1.86 percent with semaglutide, and -12.4 kg of weight loss versus -6.2 kg, over 40 weeks^[1]. The dual agonist crossed the non-inferiority threshold and met the superiority threshold for both endpoints.

SURPASS-CVOT, reported in 2025, was the cardiovascular outcomes trial — 13,165 adults with type 2 diabetes and established atherosclerotic cardiovascular disease randomized to tirzepatide titrated to 5-15 mg or dulaglutide 1.5 mg, followed for a median of four years. Tirzepatide met non-inferiority for three-point major adverse cardiovascular events (MACE), with an 8 percent relative MACE reduction and a 16 percent lower all-cause mortality versus dulaglutide^[14]. This is the cardiovascular safety record on which the FDA-approved tirzepatide product was built.

SURMOUNT — obesity

SURMOUNT-1 randomized 2,539 adults with obesity (BMI at or above 30, or at or above 27 with a weight-related comorbidity) without diabetes to tirzepatide 5, 10, or 15 mg or placebo, once weekly subcutaneous, for 72 weeks^[2]. Mean body-weight reductions were 15.0 percent, 19.5 percent, and 20.9 percent for the active arms, against 3.1 percent for placebo. Approximately nine in ten participants on tirzepatide lost weight. Body composition analysis indicated that fat mass reduction was roughly three-fold greater than lean mass reduction.

SURMOUNT-2 extended the obesity indication into the population with type 2 diabetes: 938 adults with BMI at or above 27 and HbA1c 7 to 10 percent, randomized for 72 weeks. Mean weight loss was 13.4 percent at 10 mg and 15.7 percent at 15 mg, versus 3.3 percent on placebo^[5]. The safety profile matched the broader incretin class.

SURMOUNT-4 addressed the durability question directly. After a 36-week open-label tirzepatide lead-in, 670 adults were randomized to continued tirzepatide or placebo for 52 weeks. Participants withdrawn to placebo regained roughly 14 percent of body weight, while those who continued tirzepatide lost an additional 6.7 percent — a between-group difference of 20.4 percentage points^[15]. Whatever model of pharmacotherapy is used, SURMOUNT-4 documents that maintained dosing is required to sustain the effect.

SURMOUNT-5, published in 2025, was the first head-to-head obesity trial against semaglutide 2.4 mg. Over 72 weeks in 751 adults, tirzepatide produced 20.2 percent mean weight reduction versus 13.7 percent for semaglutide — a 47 percent relative difference, with -22.8 kg versus -15.0 kg absolute weight loss^[3].

Adjacent indications and ongoing programs

SURMOUNT-OSA enrolled 469 adults with moderate-to-severe obstructive sleep apnea and obesity across two parallel sub-trials, one with PAP therapy and one without. Over 52 weeks, tirzepatide reduced apnea-hypopnea index (AHI) by approximately 25 events per hour and produced roughly 20 percent mean body-weight loss^[17]. The trial supported the December 2024 FDA approval — the first-ever approval of a pharmacotherapy for OSA.

SUMMIT studied 731 adults with heart failure with preserved ejection fraction (HFpEF, defined as LVEF at or above 50 percent) and BMI at or above 30. Over a median 104 weeks, tirzepatide reduced the composite of cardiovascular death or worsening heart-failure events by 38 percent (hazard ratio 0.62, 95% CI 0.41 to 0.95), and improved Kansas City Cardiomyopathy Questionnaire score, 6-minute walk distance, and hsCRP^[18].

SYNERGY-NASH enrolled 190 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and stage 2 or 3 fibrosis. At 52 weeks, 51 to 62 percent of tirzepatide-treated participants — across the 5, 10, and 15 mg arms — achieved MASH resolution without fibrosis worsening, versus 10 percent on placebo^[19]. Fibrosis improvement was observed as a secondary endpoint.

Safety record — for the FDA-approved product

Across the trial program and post-marketing surveillance, the most frequent adverse events are gastrointestinal: nausea, diarrhea, vomiting, and constipation, concentrated during dose escalation and decreasing with continued exposure^[20]. Pancreatitis has been observed at roughly 0.2 percent. Cholelithiasis and acute kidney injury — often secondary to volume depletion from GI losses — are documented but less frequent.

The FDA-approved label carries a boxed warning for thyroid C-cell tumors based on 2-year rat carcinogenicity studies, which documented dose-dependent C-cell adenomas and carcinomas at exposures at or above 0.5x the human exposure at the maximum recommended dose^[21]. Human relevance is uncertain — rodent C-cells express GLP-1 receptors at substantially higher levels than human C-cells — but the boxed warning contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

A central point for the purposes of this site: every figure in this section comes from studies of the FDA-approved product, manufactured under Good Manufacturing Practice (GMP) standards, with documented identity, purity, and potency. None of the SURPASS, SURMOUNT, SUMMIT, SYNERGY-NASH, or SURPASS-CVOT data should be assumed to apply to compounded copies, repackaged vials, or import "research peptide" products. There is no equivalent clinical evidence base for those.